TEMHealthcare · Health Information ServicesThe 16 Wall Street analysts covering Tempus AI, Inc. hold a median 12-month price target of $59 — +13.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 8 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Tempus AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (83): Analysts have, on balance, been raising their forecasts.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Tempus AI, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on TEM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +13.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | $58 → $56 |
| 3 Aug 2026 | BTIG | Maintains | Buy | $80 → $70 |
| 3 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $64 → $56 |
| 3 Aug 2026 | Stifel | Maintains | Hold | $60 → $50 |
| 31 July 2026 | Needham | Reiterates | Buy | $75 |
| 20 July 2026 | Needham | Reiterates | Buy | $75 |
| 20 July 2026 | Needham | Reiterates | Buy | — |
| 16 July 2026 | Guggenheim | Maintains | Buy | $60 → $65 |
| 16 July 2026 | Guggenheim | Maintains | Buy | — |
| 1 July 2026 | Freedom Capital Markets | Initiates | Hold | — |
| 1 July 2026 | Freedom Capital Markets | Initiates | Hold | $59 |
| 1 June 2026 | BTIG | Reiterates | Buy | — |
| 1 June 2026 | Needham | Reiterates | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 May 2026 | BTIG | Maintains | Buy | — |
| 6 May 2026 | TD Cowen | Maintains | Buy | — |
| 13 Apr 2026 | Jefferies | Initiates | Underperform | — |
| 30 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 11 Mar 2026 | Needham | Reiterates | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 20% of US stocks
Cheaper than 5% of US stocks
Cheaper than 94% of US stocks
Higher than 72% of US stocks
Higher than 61% of US stocks
Higher than 78% of US stocks
Higher than 22% of US stocks
Higher than 16% of US stocks
Higher than 18% of US stocks
Higher than 27% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TEM appears on the weeks it earns a place.
CellCarta announced a strategic collaboration with Tempus AI, adding Tempus as its second commercial laboratory partner under the CDx Accelerator Model to support oncology-focused access.
Why it matters — The collaboration expands Tempus's role in companion diagnostic commercialization within an oncology-focused lab network.
Tempus AI announced that study results for PRISM2, a multimodal pathology foundation model developed with Microsoft researchers, were published in Nature Medicine, demonstrating best-in-class performance on diagnostic and prognostic tasks using simple prompts.
Why it matters — For Tempus watchers, publication in a top-tier journal like Nature Medicine signals external validation and potential competitive advantage for the company's AI-driven pathology capabilities.
Julie & Holleman LLP, a shareholder rights firm, announced it is investigating Tempus AI's proposed acquisition of Personalis, Inc., in which Tempus is an existing shareholder and strategic partner. The firm is inviting Personalis shareholders potentially interested in pursuing claims to contact it.
Why it matters — The announced investigation signals potential legal scrutiny or shareholder claims that could affect Tempus AI's proposed acquisition of Personalis.
Tempus AI Inc. shares traded lower on Friday as market participants digested a post-earnings reset in expectations for the company.
Why it matters — The stock price decline following an earnings reset signals a shift in how the market is valuing Tempus AI after its most recent financial results.
Tempus AI shares rose 6.6% after reporting a narrower second-quarter loss than expected, revenue that beat estimates, and raised 2026 sales guidance driven by growth in diagnostics and data.
Why it matters — Investors tracking TEM would note the narrower loss, revenue beat, and higher forward guidance as signs of improving financial performance and growth momentum.
The 16 Wall Street analysts covering Tempus AI, Inc. have a median 12-month price target of $59, with estimates ranging from $35 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Tempus AI, Inc., 8 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Tempus AI, Inc. 27 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Aug 2026, Tempus AI, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +13.4% from the last close, and Ticker Nerd's factor model ranks Tempus AI, Inc. 27 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tempus AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $100 over the next 12 months.
Tempus AI, Inc. returned -11.4% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to clinical and molecular data to support medical decision-making.
The most recent item we track (PRNewsWire, 6 Aug 2026): "CellCarta Adds Tempus to CDx Commercialization Lab Network". CellCarta announced a strategic collaboration with Tempus AI, adding Tempus as its second commercial laboratory partner under the CDx Accelerator Model to support oncology-focused access.
Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to clinical and molecular data to support medical decision-making. The company operates a data and analytics platform designed to structure, integrate, and analyze diverse healthcare information, including genomic, imaging, and electronic health record data, with the goal of enabling more precise and personalized care. Tempus AI focuses on multiple therapeutic areas such as oncology, neuropsychiatry, cardiology, infectious disease, and radiology, providing tools that help clinicians interpret complex data and select appropriate diagnostics or treatment options. Its offerings include intelligent diagnostics that use AI, including generative AI, to make laboratory testing more accurate and tailored to individual patients. Headquartered in Chicago, Illinois and founded in 2015, Tempus AI today plays a notable role in the health information services segment, serving healthcare providers, life sciences companies, and research institutions that rely on data-driven insights to improve clinical workflows and patient outcomes.
CEO Mr. Eric P. Lefkofsky J.D. · 3,800 employees · United States · https://www.tempus.com